Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Simulations Plus (SLP – Research Report) and Viridian Therapeutics (VRDN – Research Report) with bullish sentiments.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Simulations Plus (SLP)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Simulations Plus today. The company’s shares closed last Monday at $19.50.
According to TipRanks.com, Hewitt is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Simulations Plus with a $20.50 average price target.
See today’s best-performing stocks on TipRanks >>
Viridian Therapeutics (VRDN)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Viridian Therapeutics. The company’s shares closed last Monday at $32.75.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $41.48, a 29.1% upside from current levels. In a report issued on December 10, Wedbush also maintained a Buy rating on the stock with a $47.00 price target.
